15Jun 2017

Consort Medical Plc (LSE:CSRT) Full year results

Consort Medical plc (LSE: CSRT) (“Consort”, “Consort Medical” or the “Group”), a leading, global, single source drug and delivery device company, today announces its audited results for the year ended 30 April 2017.

2Jun 2017

Motif Bio Plc (AIM:MTFB) Result of Placing

Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces the successful completion of the Placing (as defined below) which was announced earlier today.

2Jun 2017

Motif Bio Plc (AIM:MTFB): Proposed Placing

Motif Bio plc (AIM:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces its intention to raise approximately £19.4 million (US$25 million), before expenses, by way of a conditional placing with new and existing investors to fund the further development of iclaprim, the Company’s novel antibiotic candidate.

23May 2017

SkinBioTherapeutics PLC (AIM:SBTX) Extension of research contract with University of Manchester

SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that, as envisaged in the Company’s Admission Document dated 29 March 2017, it has agreed an eight month extension to its research contract with the University of Manchester to June 2018. This contract extension includes provision for the appointment of a second technician to the Company. This will increase the Company’s ability to develop its SkinBiotix® platform.

3May 2017

Optibiotix (AIM:OPTI) Presentation of abstract at conference

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has had an abstract accepted for presentation at the International Scientific Conference on Probiotics and Prebiotics in Budapest, Hungary from 20 – 22 June 2017 (IPC2017).

6Apr 2017

SkinBioTherapeutics Plc lists on FTSE (AIM:SBTX)

SkinBioTherapeutics plc (AIM: SBTX, the “Company”), a life science company focused on skin health, announces the commencement of dealings in its Ordinary Shares on AIM 5 March 2017 under the ticker code SBTX and the ISIN number: GB00BF33H870.

Page 1 of 212
DON’T MISS OUT!
Subscribe To Our Newsletter
Be the first to get latest updates and exclusive content straight to your email inbox.
Stay Updated
Give it a try, you can unsubscribe anytime.
close-link